BrainStorm Cell Therapeutics [5] released new data on potential biomarkers from its Phase 2 trial investigating NurOwn [6], the company’s cell therapy for amyotrophic lateral sclerosis (ALS), at the International Symposium on ALS/MND [7] meeting held in Boston last week.
Both these findings and an ongoing Phase 3 trial, now recruiting patients in the U.S., were discussed in greater detail with Ralph Kern, MD, Brainstorm’s chief operating officer and chief medical officer, in an interview to ALS News Today [8] days before the Dec. 8–10 symposium.
NurOwn [9]is an autologous adult stem cell therapy technology [10] that uses a patient’s own stem cells — specifically, bone marrow-derived mesenchymal stem cells (MSC) — and differentiates them into neuron-supporting cells.
Its cells work by secreting nerve-growth factors known to protect existing motor neurons and promote motor neuron growth, with the potential of helping to re-establish nerve-muscle interaction.
More at: https://alsnewstoday.com/2017/12/12/brainstorm-cmo-talks-in-interview-about-nurown-and-potential-as-therapy-for-als-with-rapid-progression/